Partner, European and UK Patent Attorney

80 Turnmill Street
London, EC1M 5QU
United Kingdom

+442030778600

Patent star 2025


Jurisdictions:

United Kingdom (England)

Practice areas:

Patent
Patent strategy & counseling

Industry sectors:

Electronics
ICT & software
Medical devices


Mark handles a broad spectrum of work originating from the UK and USA, including drafting, filing and prosecuting patent applications as well as advising on third party patents as part of due diligence and freedom to operate exercises. He has a special focus on medical devices and medical machines and acts for a number of medical technology clients. He visits patent applicants and attorneys regularly in the USA.

Mark is extremely experienced in contentious proceedings before the European Patent Office and usually attends several Opposition Division hearings each year, as well as attending a significant number of Examining Division and Board of Appeal hearings. Mark has attended over 100 EPO hearings and has acted in a number of commercially important cases, both defending his clients' patents and attacking patents owned by competitors.

Mark has detailed knowledge of the intricacies of European prosecution and is also responsible within J A Kemp for monitoring changes in patent law worldwide.

As well as European and British patent work, Mark has substantial experience in obtaining patent protection for clients abroad, especially in the USA, Japan, Korea and China. Mark is experienced in drafting, filing and prosecuting families of applications abroad and is able to coordinate patent filing programmes in an efficient and cost-effective manner.

 

Year Joined Firm: 1997

Education/Alumni: University of Oxford, Masters Degree in Engineering Science

Network Memberships:

  • Fellow of the Chartered Institute of Patent Attorneys (CIPA)
  • Member of the Institute of Professional Representatives before the European Patent Office (EPI)
  • Affiliate membership of the Institute of Physics and Engineering in Medicine (IPEM)
  • Member of the OBN Medtech Advisory Board